FDA approved therapy

Tenvie Therapeutics Doses First Patient in TNV262 Trial

Brisbane, California, USA, April 6, 2026 First-in-Human Study Targets Inflammation Pathways In a significant milestone for clinical-stage biotech innovation,...

By cGxPwire Editor
April 7, 2026

M&A

Neurocrine Acquires Soleno to Boost Rare Disease Portfolio

San Diego & Redwood City, California, USA, April 6, 2026 Strategic Acquisition Strengthens Rare Disease Leadership In a major...

By cGxPwire Editor
April 7, 2026

Pharma

Talicia U.S. Commercialization Launch Expands Reach

February 25, 2026 – Raleigh, North Carolina & Tel-Aviv, Israel RedHill Biopharma Ltd. has announced the full operational and...

By cGxPwire Editor
February 25, 2026

.VC

BridgeBio Secures $300 Million Upfront Through Royalty Monetization of BEYONTTRA in Europe

PALO ALTO, CA., June 30, 2025 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), the biopharmaceutical company dedicated to developing transformative...

By cGxPwire Editor
August 25, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

FDA approved therapy

Tenvie Therapeutics Doses First Patient in TNV262 Trial

Neurocrine Acquires Soleno to Boost Rare Disease Portfolio

Talicia U.S. Commercialization Launch Expands Reach

BridgeBio Secures $300 Million Upfront Through Royalty Monetization of BEYONTTRA in Europe